CAPTEM (Capecitabine and Temozolomide)
Phase 3Small molecule
CAPTEM (Capecitabine and Temozolomide) is one of 46 small molecule programs targeting Pancreatic Neuroendocrine Tumor. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
60 competitors in Pancreatic Neuroendocrine Tumor
#DrugCompanyPhaseTrials
1DTIC-Dome
BayerApproved
Afinitor
NovartisPhase 3
Sandostatin
Sun PharmaApproved
Glucophage
EMD SeronoApproved
Octreotide
Johnson & JohnsonPhase 3
Sutent
PfizerPhase 2
FOLFOX
AstraZenecaPhase 3
Zepzelca
Jazz PharmaceuticalsPhase 2
Ibrance
PfizerPhase 2
Sandostatin
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- IITM Solucin GmbH